Physician profile
Wesley Baas
NPI 1508246448
$5,746.21
in general payments reported to CMS, 2019-2025
22 companies · $598 in 2025
The $598 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,249 · 2020: $68.10 · 2021: $70.46 · 2022: $1,047 · 2023: $1,840 · 2024: $874 · 2025: $598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,867 · Consulting Fee: $400 · Travel and Lodging: $44.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,867.26 |
| Consulting Fee | $400.00 |
| Travel and Lodging | $44.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,596.38 | 2019-2025 | Ams 700, Rezum Generator, Lithoclast |
| Cook Medical LLC | $361.98 | 2019-2023 | Resonance |
| Teleflex LLC | $229.19 | 2023-2025 | Urolift |
| Coloplast Corp | $224.22 | 2023-2025 | Titan |
| Endo Pharmaceuticals INC. | $209.83 | 2022-2023 | Aveed, Edex, Xiaflex |
| Endo USA, INC. | $200.00 | 2024 | Xiaflex |
| Janssen Biotech, INC. | $170.33 | 2019-2024 | Erleada, Akeega |
| Urogen Pharma, INC. | $150.56 | 2022-2024 | |
| Astellas Pharma US INC | $133.65 | 2019-2023 | Xtandi |
| Antares Pharma, INC. | $88.76 | 2023-2025 | Xyosted, Nocdurna, Tlando |
| Halozyme INC | $76.22 | 2023 | |
| Abbvie INC. | $40.70 | 2023-2024 | Botox |
| Convatec INC. | $38.13 | 2023 | |
| Biotissue Holdings INC. | $37.37 | 2024 | |
| Sumitomo Pharma America, INC. | $35.74 | 2023-2024 | Orgovyx |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verity Pharmaceuticals INC. | $31.13 | 2024 | Tlando |
| Valencia Technologies Corporation | $25.75 | 2025 | Ecoin Device Kit |
| Kerecis Limited | $25.08 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Procept Biorobotics Corporation | $19.34 | 2024 | Aquabeam System |
| Tolmar, INC. | $18.48 | 2024 | |
| Ferring Pharmaceuticals INC. | $17.52 | 2024 | Adstiladrin |
| Laborie Medical Technologies Corp. | $15.85 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wesley Baas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.